Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukemia

Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes

Bone Marrow Transplantation volume 49, pages 1022–1028 (2014)Cite this article

Subjects

Abstract

Newer cytogenetic scoring systems for myelodysplastic syndromes (MDSs), like cytogenetic stratification of the revised international prognostic scoring system (IPSS-R) or monosomal karyotype, may also improve outcome prediction after hematopoietic SCT (HCT). We compared the prognostic value of specific cytogenetic abnormalities, IPSS-R karyotype and monosomal karyotype for HCT outcome in 98 patients with MDS and AML post MDS. Higher-risk IPSS-R karyotype, 3q21q26 and transformation to AML before HCT were associated with increased cumulative incidence of relapse (CIR), whereas OS was adversely influenced by del 5q/−5, abnormalities of chromosomes 11 and 17 and cytogenetic IPSS-R very poor category. Karyotype with ⩽2 abnormalities and no abnormalities of chromosomes 3, 5, 7, 11 and 17 was an independent prognostic factor of lower CIR (hazard ratio (HR)=0.2, P=0.01) and longer OS (HR=0.5, P=0.03). In conclusion, some specific cytogenetic abnormalities and high cytogenetic complexity, as reflected by IPSS-R very poor karyotype, rather than monosomal karyotype, were associated with higher CIR and shorter OS after HCT. Conversely, results were encouraging in patients lacking those abnormalities, who may be very good candidates for HCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1992; 51: 189–199.

    Article  Google Scholar 

  2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. ARC press: Lyon, France, 2008.

  3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  4. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820–829.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26: 4791–4797.

    Article  PubMed  Google Scholar 

  7. Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 205–213.

    Article  PubMed  Google Scholar 

  8. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM et al. Impact of cytogenetics on outcome of de novo and therapy related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007; 13: 655–664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 2010; 45: 877–885.

    Article  CAS  PubMed  Google Scholar 

  10. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012; 120: 1398–1408.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J et al. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. Leukemia 2013; 27: 879–888.

    Article  CAS  PubMed  Google Scholar 

  12. Wang SA, Jabbar K, Chen SS, Galili N, Vega F, Jones D et al. Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 2010; 24: 740–747.

    Article  CAS  PubMed  Google Scholar 

  13. CIBMTR Forms manual: pre-TED (Form2400). Document number A00413 version 2.4.

  14. Kaplan E, Meier P . Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  15. Peto R, Peto J . Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972; 135: 185–198.

    Article  Google Scholar 

  16. Fine J, Gray R . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  17. Cox DR . Regression models and life tables. J R Stat Soc B 1972; 34: 187–220.

    Google Scholar 

  18. Middeke JM, Beelen D, Stadler M, Göhring G, Schlegelberger B, Baurmann H et al. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-. Blood 2012; 120: 2521–2528.

    Article  CAS  PubMed  Google Scholar 

  19. Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol. 2013; 31: 916–922.

    Article  PubMed  Google Scholar 

  20. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011; 25: 266–270.

    Article  CAS  PubMed  Google Scholar 

  21. Belli CB, Bengió R, Aranguren PN, Sakamoto F, Flores MG, Watman N et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011; 86: 540–545.

    Article  PubMed  Google Scholar 

  22. Itzykson R, Thépot S, Eclache V, Quesnel B, Dreyfus F, Beyne-Rauzy O et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011; 25: 1207–1209.

    Article  CAS  PubMed  Google Scholar 

  23. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al. Monosomal karyotype in MDS: Explaining the poor prognosis? Leukemia 2013; 27: 1988–1995.

    Article  CAS  PubMed  Google Scholar 

  24. Nevill TJ, Shepherd JD, Sutherland HJ et al. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 205–213.

    Article  PubMed  Google Scholar 

  25. Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol 2012; 30: 4533–4540.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

CK is indebted to Professor Pierre Fenaux for critical reviewing of the manuscript

Author information

Authors and Affiliations

  1. Hematology Department and Bone Marrow Transplantation Unit, G. Papanicolaou Hospital, Exochi, Thessaloniki, Greece

    C Kelaidi, I Tzannou, I Baltadakis, I Batsis, D Mallouri, A Spyridonidis, S Gigantes, P Tsirigotis, I Apostolidis, A Athanasiadou, K Manola, A Anagnostopoulos, N Harhalakis, I Sakellari & D Karakasis

Authors
  1. C Kelaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Tzannou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I Baltadakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Batsis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Mallouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Spyridonidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Gigantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Tsirigotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I Apostolidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Athanasiadou
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K Manola
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Anagnostopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. N Harhalakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. I Sakellari
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. D Karakasis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Kelaidi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kelaidi, C., Tzannou, I., Baltadakis, I. et al. Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes. Bone Marrow Transplant 49, 1022–1028 (2014). https://doi.org/10.1038/bmt.2014.87

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.87

Search

Advanced search

Quick links